Nachrichten zur Eli Lilly & Co Aktie

Eli Lilly (LLY) Stock Slides as Market Rises: Facts to Know Before You Trade

Eli Lilly (LLY) closed at $762.18 in the latest trading session, marking a -1.23% move from the prior day.…

Should You Invest in This Under-the-Radar Weight Loss Stock?

Key PointsRhythm Pharmaceuticals lone approved product currently generates minimal sales.However, recent clinical progress could help change that in the coming…

Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.

Key PointsPresident Trumps tariffs could erode healthcare companies profits, but some may perform well regardless.Eli Lilly and Novartis have taken…

Is Nvidia Stock Too Expensive to Buy Now?

Key PointsData center growth is slated to continue for some time.Nvidias GPUs are unrivaled in the AI space. Many stocks…

Eli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today?

LLYs explosive growth from Mounjaro and Zepbound outpaces MRKs Keytruda-led gains, despite valuation concerns.…

Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly’s Zepbound

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcickis nonprofit…

Eli Lilly (LLY) Dips More Than Broader Market: What You Should Know

In the most recent trading session, Eli Lilly (LLY) closed at $771.75, indicating a -3.45% shift from the previous trading…

Top Research Reports for Eli Lilly, Netflix & GE Aerospace

LLY, NFLX, and GE lead todays top stock picks, with strong growth drivers but face headwinds from pricing, rivals, and…

3 Dividend Growth Stocks to Buy and Hold

Key PointsAbbott Laboratories is a dividend growth machine thats known for consistency.AbbVies dividend has more than quadrupled since 2013.Eli Lilly…

Can Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?

LLY rides high on surging demand for Mounjaro and Zepbound, now nearly half its revenues ahead of Q2 earnings.…

Eli Lilly Comes Out As ADA Winner

…

3 Reasons I Bought Novo Nordisk Stock Instead of Eli Lilly

Key PointsNovo Nordisks beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year.Eli Lillys…

Eli Lilly (LLY) Beats Stock Market Upswing: What Investors Need to Know

In the most recent trading session, Eli Lilly (LLY) closed at $786.92, indicating a +1.19% shift from the previous trading…

Eli Lilly Q2 preview: BofA sees focus on policy risks, obesity pipeline

Bank of America on Wednesday reiterated its “Buy” rating and $1,000 price objective on Eli Lilly and Co (NYSE:LLY), ahead…

3 Underrated Dividend Growth Stocks to Buy and Hold for Years

Key PointsThe stocks listed here each increased their dividend payments by more than 10% recently.Although their yields may look unimpressive,…

3 No-Brainer Stocks to Buy in July

Key PointsAbbVie offers something for every investor.Eli Lilly could be overdue for a big rally.Vertex Pharmaceuticals is in a new…

Better Growth Buy: Eli Lilly vs. Viking Therapeutics @themotleyfool #stocks $LLY $GS $NVO $VKTX

…

Better Growth Buy: Eli Lilly vs. Viking Therapeutics

Key PointsEli Lilly is a leader in the weight loss drug market, generating blockbuster revenue.Viking Therapeutics recently launched a phase…

2 Stocks to Buy on the Dip and Hold for 10 Years

Key PointsNovo Nordisks shares look attractive after a terrible performance over the past 12 months.DexCom has significant room to grow…

2 Dividend Growth Stocks to Buy and Hold Forever

Key PointsInvesting in attractive dividend growth stocks can lead to superior long-term returns.The two healthcare companies below generally deliver excellent…

Why I Think Viking Therapeutics Is an Asymmetric Growth Opportunity

Key PointsWall Streets smartest money has quietly amassed over $150 million in bullish positions, with Goldman Sachs eliminating all downside…

This GLP-1 Stocks Bad News Could Be a Big Win for Eli Lilly and Novo Nordisk @themotleyfool #stocks $AMGN

…

This Dirt Cheap Healthcare Stock Could Be a Hidden Artificial Intelligence (AI) Opportunity (Hint: Its Not Eli Lilly)

Artificial intelligence (AI) has the potential to transform several different areas of the healthcare industry.…

Which Stock Will Dominate the Weight Management Market Through 2030?

The market for weight management medicines has been the hottest therapeutic area in the past two years. Plenty of companies…

NVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now?

Eli Lilly edges ahead of Novo Nordisk as the stronger obesity bet, backed by robust sales growth, pipeline depth and…

This Vanguard ETF Turned $10,000 Into $108,900 -- and AI Could Accelerate Its Growth

Stocks are on fire this summer. Driven primarily by artificial intelligence (AI) and its offshoots like advanced robotics, tech stocks…

Why This Weight Loss Drug Companys Stock Surged Today

Shares in biopharmaceutical company Viking Therapeutics (NASDAQ: VKTX) were up by 6.3% at 12:30 a.m. ET today. The move likely…

Eli Lilly: Ive Learned Not To Fight Against The Market (Downgrade)

…

Can LLYs Next-Generation Obesity Pipeline Fuel Further Growth?

Eli Lilly bets on next-generation obesity candidates like orforglipron and retatrutide to sustain growth amid rising competition.…

Buy Eli Lilly While The Market Hesitates And Let Time Make You Dominate

…

Teslas Robotaxi Rollout

In this podcast, Motley Fool Chief Investment Officer Andy Cross and contributors Jason Hall and Matt Frankel discuss: Fair Isaac Corp.…

3 Reasons to Buy Eli Lilly Stock Like Theres No Tomorrow

Eli Lilly (NYSE: LLY) has been on fire over the past two years. The drugmaker has generated excellent financial results…

Abbott jumps on RFK Jr. health push — plus, reviews of Eli Lillys obesity drug data

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of…

Eli Lilly: It Is A Bet On Human Longevity

…

Eli Lilly (LLY) Surpasses Market Returns: Some Facts Worth Knowing

The latest trading day saw Eli Lilly (LLY) settling at $770.64, representing a +1.04% change from its previous close.…

IWF Is a Great Choice for Most, But I Like VUG ETF Better

The iShares Russell 1000 Growth ETF (NYSEMKT: IWF) is one of the largest and most popular exchange-traded funds (ETFs) focused…

Chinese Biotech Showcases Challenger to Eli Lilly’s Obesity Drug

An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a…

Key deals this week: Couchbase, Eli Lilly, NTT Data, QXO, US Steel and more

…

Lilly expects orforglipron obesity results in third quarter

Eli Lilly said on Saturday its experimental pill orforglipron helped diabetics lose weight and lower their blood sugar, and the…

Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says

Treatments designed to help patients preserve muscle while losing weight with popular obesity drugs by Eli Lilly and Novo Nordisk…

Eli Lilly says India response to obesity drug Mounjaro is positive, will focus on meeting demand

Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing…

Missed Out on Eli Lillys 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.

Eli Lilly (NYSE: LLY) has been one of the hottest healthcare stocks to own in recent years, thanks in large…

Missed Out on Eli Lillys 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside. @themotleyfool #stocks $VKTX $LLY $ALT

…

dpa-AFX ProFeed